Peptides for Fatty Liver: Evidence and Safety

Peptides for fatty liver disease represent one of the most rapidly evolving areas in hepatology and metabolic medicine. Fatty liver disease, particularly metabolic dysfunction-associated steatotic liver disease (MASLD), affects a significant proportion of UK adults and is closely linked to obesity, type 2 diabetes, and insulin resistance. Peptide-based medicines, including GLP-1 receptor agonists such as semaglutide and the dual agonist tirzepatide, are showing considerable promise in reducing liver fat and improving metabolic health. This article explains how these treatments work, what the current UK evidence shows, and how they fit alongside lifestyle management.

What is fatty liver disease and how does it develop?

Fatty liver disease occurs when excess fat accumulates in liver cells, impairing function. MASLD, the most common form in the UK, is linked to obesity, type 2 diabetes, and insulin resistance, and can progress to fibrosis or cirrhosis without intervention.

Fatty liver disease occurs when excess fat accumulates within liver cells, impairing normal liver function over time. The two principal forms recognised in UK clinical practice are metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD) and alcohol-related liver disease (ALD). MASLD is now the more common form, closely linked to obesity, type 2 diabetes, insulin resistance, and raised blood lipids.^[19][24]

The condition develops through a combination of metabolic and inflammatory processes. When the liver receives more fatty acids than it can process or export, fat droplets accumulate within hepatocytes. In some individuals, this progresses to metabolic dysfunction-associated steatohepatitis (MASH), characterised by liver cell inflammation and damage. Without intervention, a proportion of people develop fibrosis, cirrhosis, or, in rare cases, liver cancer.

NICE guidance (NG49) highlights that MASLD is often silent in its early stages. Importantly, liver function tests (LFTs) can be entirely normal in MASLD, so a normal result does not exclude the diagnosis in people with relevant risk factors. Risk factors include:

• Body mass index (BMI) above 25 kg/m² (or lower thresholds in South Asian populations)

• Type 2 diabetes or pre-diabetes

• Hypertriglyceridaemia or low HDL cholesterol

• Hypertension

NICE NG49 recommends non-invasive fibrosis risk stratification for people with MASLD. This typically involves calculating a FIB-4 score or NAFLD fibrosis score as a first step, followed by an enhanced liver fibrosis (ELF) test where indicated. People with scores suggesting significant fibrosis should be referred to hepatology for further assessment. Early identification matters because lifestyle intervention at the steatosis stage can reverse fat accumulation before significant fibrosis develops.

What are peptides and how might they help a fatty liver?

Peptides such as GLP-1 receptor agonists reduce hepatic fat primarily by promoting weight loss and improving insulin sensitivity, reducing the flux of fatty acids to the liver. Tirzepatide, acting on both GLP-1 and GIP receptors, shows greater reductions in body weight and emerging evidence of greater hepatic steatosis reduction.

Peptides are short chains of amino acids that act as signalling molecules in the body, and several naturally occurring peptides play a direct role in regulating metabolism, appetite, and liver fat handling. In the context of fatty liver disease, the most clinically relevant peptides are those that mimic or enhance the action of gut-derived hormones, particularly glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and fibroblast growth factor 21 (FGF21).

GLP-1 receptor agonists, such as semaglutide (available in the UK as Ozempic for type 2 diabetes and Wegovy for weight management), reduce hepatic fat primarily through indirect mechanisms:^[12][13]

• Reducing caloric intake by slowing gastric emptying and increasing satiety

• Improving insulin sensitivity, which reduces the flux of free fatty acids to the liver

• Reducing hepatic lipogenesis as a downstream consequence of improved metabolic control and weight loss

The extent to which GLP-1 receptor agonists act directly on hepatocytes is not firmly established; current evidence suggests the predominant benefit on liver fat is mediated indirectly through weight loss and improved insulin sensitivity rather than through direct receptor-mediated effects on liver cells.

Tirzepatide (Mounjaro), which is MHRA-authorised in the UK for both type 2 diabetes and chronic weight management, acts on both GLP-1 and GIP receptors simultaneously.^[9][2] Clinical trial data, including the SURMOUNT programme, indicate that this dual agonism produces greater reductions in body weight than GLP-1 agonism alone, and emerging data from liver-fat substudies suggest correspondingly greater reductions in hepatic steatosis, though head-to-head liver-specific comparisons remain limited.^[10][11]

Other investigational peptides, including FGF21 analogues (such as efruxifermin and pegozafermin) and peptide YY (PYY) analogues, are being studied for their potential to reduce hepatic steatosis. These remain in clinical trial phases and are not currently available outside authorised research settings in the UK. The term "peptides for fatty liver" therefore covers a broad and evolving landscape, ranging from licensed medicines to experimental compounds.

What does the current UK evidence say about peptide treatments?

The strongest evidence centres on semaglutide and tirzepatide, with trials showing MASH resolution and, for tirzepatide, significant fibrosis improvement. Neither medicine currently holds a UK licence for MASLD or MASH, making use in liver disease off-label and specialist-led.

The strongest UK-relevant evidence for peptide-based treatment of fatty liver currently centres on GLP-1 receptor agonists, particularly semaglutide. The NASH trial published in the New England Journal of Medicine (Newsome et al., 2021) evaluated once-daily subcutaneous semaglutide 0.4 mg in people with MASH. The primary endpoint was NASH resolution without worsening of fibrosis; this was met more frequently in the semaglutide group than with placebo, though the key secondary endpoint of fibrosis improvement did not reach statistical significance. Larger Phase 3 trials, including the ESSENCE study evaluating semaglutide 2.4 mg in MASH, have since reported more encouraging results on both steatohepatitis resolution and fibrosis improvement, though readers should note that full peer-reviewed publication details should be verified against the primary source.

For tirzepatide, the SYNERGY-NASH trial (published in the New England Journal of Medicine, 2024) showed that tirzepatide produced statistically significant MASH resolution and fibrosis improvement compared with placebo, representing a meaningful step forward in the evidence base.^[4]

It is important to note that neither semaglutide nor tirzepatide currently holds a specific UK licence for the treatment of MASLD or MASH; their MHRA authorisations cover type 2 diabetes and weight management respectively.^[22][23] Use in liver disease specifically would therefore be off-label, should be specialist-led, and prescribing decisions must reflect local policies and the individual clinical context. NICE has not yet issued a technology appraisal specifically recommending GLP-1 or dual agonist therapies for MASLD or MASH (see nice.org.uk for current guidance status). Clinicians and patients considering these options should discuss the evidence base and off-label status with their hepatology or gastroenterology team.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where licensed weight-management treatments may be considered where clinically appropriate. Investigational peptides such as FGF21 analogues remain available only within authorised clinical trials.

Are peptide therapies safe, and what side effects should I watch for?

GLP-1 and dual agonist medicines have well-characterised safety profiles; the most common side effects are gastrointestinal. Serious but less common risks include acute pancreatitis, gallbladder disease, and worsening of diabetic retinopathy.

Licensed peptide-based medicines used in the context of fatty liver, primarily GLP-1 receptor agonists and dual GLP-1/GIP agonists, have well-characterised safety profiles established through large clinical trial programmes and post-marketing surveillance. The most commonly reported side effects are gastrointestinal and include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These effects are typically dose-dependent and tend to diminish after the initial weeks of treatment.

Severe or persistent vomiting and diarrhoea can lead to dehydration, which may in turn affect kidney function. If you are unable to keep fluids down, seek medical advice promptly.

More serious but less common concerns include:

• Acute pancreatitis: The UK SmPCs for semaglutide and tirzepatide note that acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome.^[15][16] People with a history of pancreatitis should discuss this with their prescriber before starting treatment. Seek prompt medical attention if you develop persistent, severe abdominal pain.

• Gallbladder disease: Rapid weight loss associated with these medicines can increase the risk of gallstones. Symptoms such as right upper quadrant pain, fever, or jaundice warrant assessment by a GP.

• Diabetic retinopathy: In people with pre-existing pre-proliferative or proliferative diabetic eye disease, rapid improvement in blood glucose control may be associated with transient worsening of retinopathy. Ophthalmology review is advisable before starting treatment in this subgroup.

• Heart rate: A modest increase in resting heart rate has been observed with GLP-1 receptor agonists.^[1][13]

• Pregnancy, breastfeeding and contraception: GLP-1 and dual GLP-1/GIP receptor agonists are not recommended during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception during treatment. Because these medicines remain in the body for some time after stopping, the UK SmPCs advise discussing the appropriate washout period before a planned pregnancy with a prescriber. If you become pregnant while taking one of these medicines, stop treatment and contact your GP or specialist promptly.

Suspected side effects from licensed medicines should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. If you experience severe vomiting, signs of an allergic reaction, or persistent severe abdominal pain, contact NHS 111 for urgent advice or attend A&E if symptoms are life-threatening. For non-urgent concerns, speak to your GP or prescribing clinician.

Can lifestyle changes work alongside peptide-based approaches?

Lifestyle modification is the cornerstone of MASLD management and should accompany peptide therapy. A sustained weight loss of 7 to 10 per cent reduces hepatic steatosis, and combining diet, physical activity, and pharmacological support produces better outcomes than either approach alone.

Lifestyle modification remains the cornerstone of MASLD management, and evidence consistently shows that combining dietary change and physical activity with pharmacological support produces better outcomes than either approach alone. NICE NG49 recommends that all people with MASLD receive structured advice on diet, physical activity, and alcohol reduction as a first-line intervention, regardless of whether pharmacological treatment is also being considered.

A sustained reduction in body weight of 7 to 10 per cent has been shown to reduce hepatic steatosis, and losses of 10 per cent or more are associated with improvements in liver inflammation and, in some studies, fibrosis regression (Vilar-Gomez et al., Gastroenterology, 2015). Peptide-based medicines can facilitate this degree of weight loss in people who have not achieved it through lifestyle measures alone, but they work most effectively when used alongside, rather than instead of, behavioural change.

Practical lifestyle strategies that complement peptide therapy include:

• Dietary adjustment: Reducing ultra-processed foods, refined carbohydrates, and saturated fats, while increasing fibre, vegetables, and lean protein

• Physical activity: Both aerobic exercise and resistance training independently reduce liver fat. The UK Chief Medical Officers' guidelines, reflected in NHS guidance, recommend at least 150 minutes of moderate-intensity activity per week for adults^[25][26]

• Alcohol: Even in MASLD (as opposed to ALD), alcohol reduction is advisable, as alcohol contributes to hepatic fat accumulation and inflammation

• Sleep and stress: Some evidence links poor sleep quality and chronic stress to worsening metabolic health; while this area continues to develop, good sleep hygiene and stress management are reasonable general health measures

People with MASLD should be reviewed regularly by their GP or specialist team to monitor liver function, metabolic parameters, and treatment response. NICE NG49 recommends periodic reassessment of fibrosis risk using non-invasive scores (such as FIB-4 or ELF), and people whose scores indicate progression should be referred to hepatology. If liver function tests worsen or symptoms such as jaundice, significant fatigue, or abdominal swelling develop, prompt GP review is warranted.

Scientific References

1. Wegovy 2.4 mg solution for injection – Summary of Product Characteristics.
2. Tirzepatide: a medicine to manage type 2 diabetes and obesity.
3. Tirzepatide | Drugs | BNF – NICE.
4. Loomba R et al. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH). N Engl J Med. 2024..
5. NG242 Diabetic retinopathy: management and monitoring – effectiveness of intensive treatments to lower blood glucose levels.
6. Angiogenesis and inflammation in the retinopathy risk of insulin and semaglutide – a review. Int J Retina Vitreous. 2025..
7. Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study. Diabetologia. 2025..
8. New generation agents for glycemic control and diabetic retinopathy progression: what we need to know? Acta Diabetol. 2025..
9. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
10. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022..
11. Rodriguez PJ et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024..
12. First GLP-1 tablet for weight loss approved in the UK (semaglutide/Wegovy tablet). 2026..
13. Semaglutide | Drugs | BNF – NICE.
14. Sanyal AJ et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE). N Engl J Med. 2025..
15. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
16. Mounjaro (tirzepatide) – EPAR Product Information (SmPC).
17. Vilar-Gomez E et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015..
18. Glass LM et al. Total body weight loss of ≥10% is associated with regression of fibrosis in NASH. Dig Dis Sci. 2015..
19. NICE NG49: Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management.
20. NICE NG49 research recommendation: non-invasive tests for diagnosing NAFLD in adults.
21. Non-alcoholic fatty liver disease (NAFLD) – NHS.
22. Semaglutide (Wegovy) approved to treat form of liver disease.
23. NICE GID-TA11477: Semaglutide for treating moderate to advanced liver fibrosis caused by MASH.
24. NICE NG49 PDF: Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management.
25. UK Chief Medical Officers' physical activity guidelines report.
26. Physical activity guidelines for adults aged 19 to 64 – NHS.
27. Newsome PN et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021..

Frequently Asked Questions